AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Prospective Tissue Collection Research Protocol
Completed
- Conditions
- Solid Tumor
- Interventions
- Other: Tumour tissue collection
- First Posted Date
- 2018-05-08
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 221
- Registration Number
- NCT03517917
- Locations
- 🇬🇧
Research Site, Uxbridge, United Kingdom
Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Carcinoma, Squamous Cell of Head and NeckCarcinoma, Non-Small-Cell LungSmall Cell Lung Carcinoma
- Interventions
- Radiation: External beam radiation (dose level 1)Radiation: External beam radiation (dose level 2)Radiation: External beam radiation (standard)Radiation: External beam radiation (hyperfractionated)
- First Posted Date
- 2018-04-26
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 105
- Registration Number
- NCT03509012
- Locations
- 🇨🇳
Research Site, Taoyuan City, Taiwan
Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation)
Completed
- Conditions
- Ovarian Cancer
- First Posted Date
- 2018-04-23
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 846
- Registration Number
- NCT03505307
An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia
- Conditions
- Relapsed/Refractory Hairy Cell Leukemia
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT03501615
PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4)
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT03492931
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors
Phase 1
Completed
- Conditions
- Advanced Solid TumorsPancreatic CancerNon Small Cell Lung CancerOvarian Cancer
- Interventions
- Biological: MSC-1
- First Posted Date
- 2018-04-06
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 41
- Registration Number
- NCT03490669
- Locations
- 🇨🇦
Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇪🇸Hospital Universitario Vall d'Hebron, Barcelona, Spain
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients
Completed
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1700
- Registration Number
- NCT03485326
- Locations
- 🇨🇳
Research Site, Zhuji, China
Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India
Completed
- Conditions
- Ovarian Cancer
- First Posted Date
- 2018-03-20
- Last Posted Date
- 2019-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 240
- Registration Number
- NCT03471572
- Locations
- 🇮🇳
Research Site, Kolkata, West Bengal, India
Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases
Phase 1
Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: [11C]osimertinib
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4
- Registration Number
- NCT03463525
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)
Phase 2
Active, not recruiting
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 154
- Registration Number
- NCT03459846
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
© Copyright 2025. All Rights Reserved by MedPath